ss-31 dosage: Frequently asked questions

Rotate injection sites across four anatomical locations (bilateral dorsal flanks, bilateral abdominal quadrants) and reduce injection volume to <200μL per site. Injection site irritation is rare with SS-31 but can occur if reconstitution pH is not neutral (6.5-7.5) or if injection volume exceeds tissue capacity. If irritation persists, consider splitting the daily dose into two smaller injections 12 hours apart rather than one bolus. Total daily dose remains unchanged but peak local concentration is reduced. Confirm reconstitution solution is sterile and free of particulates that could cause mechanical irritation.

Administer 5mg/kg IV within 30 minutes of reperfusion. Efficacy drops sharply after this window. Post-injury SS-31 administration in a coronary occlusion model reduced infarct size by 18% when given 30 minutes post-reperfusion but showed no significant benefit at 60 minutes, compared to 43% reduction with pre-ischemic dosing. The mitochondrial permeability transition pore (mPTP) opens within minutes of reperfusion, and SS-31's protective effect depends on stabilizing cardiolipin before mPTP-mediated cell death cascades become irreversible.

Scale allometrically using body surface area (BSA) rather than direct mg/kg conversion. A 3mg/kg rodent dose converts to approximately 0.5-0.8mg/kg in primates. Primate studies published in JACC: Basic to Translational Science used 0.5mg/kg IV in a nonhuman primate heart failure model, showing similar cardioprotective effects to 3mg/kg in rodents. Larger animals have slower metabolic clearance and longer half-lives, requiring less frequent dosing. Once daily is typically sufficient compared to twice-daily in rodents. Pharmacokinetic pilot studies are essential before efficacy trials in large animal models.

Continue 1-3mg/kg subcutaneous dosing once daily for up to 12 weeks without dose adjustment. Published chronic studies extending to 16 weeks in aging models showed no tolerance development or diminished response with continuous dosing. Monitor body weight and behavioral endpoints weekly. SS-31 does not alter food intake or body composition in healthy animals, so deviations suggest off-target effects or preparation issues. Mitochondrial benefits accumulate over time rather than plateau, with maximal improvement in respiratory capacity observed at 8-12 weeks in skeletal muscle aging studies.

Rotate injection sites across at least four locations (abdomen, outer thighs, upper arms) and never inject into the same spot within 7 days. Persistent irritation despite rotation suggests one of three issues: reconstitution with standard sterile water instead of bacteriostatic water (which causes transient pH shifts), injecting cold solution directly from refrigeration (warm to room temperature for 10 minutes before injection), or contamination during reconstitution. If irritation continues after correcting these variables, the peptide batch may contain aggregates or impurities.

Administer 0.25 mg/kg subcutaneously as soon as possible after reperfusion, ideally within six hours of percutaneous coronary intervention. The EMBRACE STEMI protocol used this timing because mitochondrial oxidative stress peaks 4–12 hours post-ischemia. Earlier administration allows SS-31 to bind cardiolipin before cristae collapse and cytochrome c leakage initiate apoptosis. Delayed dosing beyond 12 hours showed diminished infarct size reduction in preclinical models, consistent with the mechanism requiring intact membrane structure to stabilize.

Administer the dose 90 minutes earlier next time. Immediate pre-exercise dosing means the peptide is still in plasma when oxidative stress peaks during the first 30 minutes of activity. Mitochondrial uptake lags behind plasma concentration by 60–90 minutes. You'll miss the protective window when ROS production is highest, and the effect will be blunted or absent. If you've already dosed immediately before, proceed with the workout but expect minimal benefit compared to optimal timing.

Use a medical-grade cooling case that maintains 2–8°C for the entire transit period. Insulin travel cases like FRIO wallets work via evaporative cooling and don't require ice or electricity. Unreconstituted lyophilised powder tolerates short-term ambient temperature (up to 25°C for 48 hours), but once mixed, temperature control is non-negotiable. Airport security permits peptide vials with a physician's letter or institutional research documentation. Never place reconstituted vials in checked luggage. Cargo holds often drop below freezing, and freeze-thaw cycles destroy peptide structure irreversibly.

Switch to mitochondrial function testing before increasing dose. Measure oxygen consumption rate (OCR), ATP production rate, or serum lactate under controlled conditions. If these markers don't improve, the bottleneck isn't cardiolipin oxidation. Alternative mechanisms to investigate include Complex I inhibition (rotenone-sensitive), uncoupling protein overexpression, or substrate limitation (carnitine deficiency impairing fatty acid oxidation). SS-31 only rescues energy production when cardiolipin damage is the rate-limiting step.

Dose 90 minutes before the session starts, not before each interval. HIIT creates repeated oxidative stress peaks across multiple bouts. SS-31's mitochondrial protection extends across the entire session once the peptide has accumulated in muscle tissue. The benefit is cumulative: each interval generates less oxidative damage than it would without SS-31, and recovery between intervals is faster. Post-session muscle damage (measured by CK elevation) is typically 20–30% lower with properly timed SS-31 administration.

Start with mid-range dosing (1.5–2mg/kg subcutaneous daily) and measure tissue-specific biomarkers at 2-week intervals. Cardiolipin-cytochrome c binding status can't be measured in vivo, but downstream markers. ATP production via luciferase assay, ROS generation via dichlorofluorescein staining, and mitochondrial membrane potential via JC-1 dye. Provide indirect evidence of SS-31 engagement. If these markers don't shift within 2 weeks, underdosing is more likely than non-response, especially if peptide purity hasn't been verified. Dose escalation to 3mg/kg with simultaneous purity testing resolves this faster than extending the protocol at subtherapeutic levels.

Discard immediately. Do not inject. Particulate formation indicates either peptide aggregation (irreversible loss of tertiary structure) or bacterial contamination. Aggregation happens when reconstitution occurs at temperatures above 25°C, when bacteriostatic water pH drifts outside 5.5–7.0 range, or when vials are shaken rather than gently swirled. Proper reconstitution produces a clear, colourless solution that remains stable under refrigeration for 14 days. Cloudiness cannot be reversed by re-filtering or re-mixing.

No. Discard it. Peptide aggregation begins within 4–6 hours above 8°C, and while the solution may appear clear, mass spectrometry would show fragmented sequences that no longer bind cardiolipin effectively. The 0.25 mg/kg dose calculation assumes full peptide integrity; degraded product at the same nominal concentration delivers a fraction of the cardioprotective effect and introduces variability that compromises research reproducibility. Store reconstituted SS-31 at 2–8°C without exception.

Administer the missed dose as soon as you remember if fewer than 10 hours have passed since the scheduled time, then resume the regular schedule. If more than 10 hours have elapsed, skip the missed dose entirely and continue with the next scheduled administration. Do not double-dose to compensate. SS-31's cardiolipin binding is saturable, and excess peptide is cleared renally without additional benefit. Missing occasional doses reduces cumulative mitochondrial protection but doesn't create rebound oxidative stress.

Discard it. Even at 20–22°C, SS-31 begins aggregating within 4 hours in plain sterile water. Bacteriostatic saline extends stability slightly, but degradation is still 10–15% at 6 hours. Aggregated peptide can't cross mitochondrial membranes efficiently. You'd be injecting inactive protein. Our team's experience: temperature excursions are the #1 preventable cause of 'non-response' in research protocols.

Review your timing, dose, and training status. If you dosed within 30 minutes of exercise, the peptide didn't accumulate in mitochondria early enough. If you're untrained or early in a training block, mitochondrial function isn't the limiting factor. Cardiovascular capacity, lactate clearance, or substrate availability likely are. SS-31 enhances performance in individuals already operating near their mitochondrial ceiling. Finally, verify peptide purity and storage conditions: SS-31 degrades rapidly at temperatures above 8°C, and degraded peptide provides no mitochondrial protection.

Start at 1mg/kg daily rather than 4mg/kg. Severe HFrEF means fewer functional mitochondria per cardiomyocyte, so saturating available cardiolipin sites happens at lower total doses. Escalating to 2mg/kg after two weeks is reasonable if 6-minute walk distance hasn't improved, but jumping directly to 4mg/kg increases adverse event risk without proportional benefit in this subset.

Prioritise dosing frequency over dose magnitude. A 1mg/kg daily protocol for 8 weeks outperforms a 3mg/kg protocol dosed twice weekly because cardiolipin stabilisation requires sustained plasma levels. Intermittent high-dose exposure allows cristae to collapse between administrations. If total peptide budget can't cover daily dosing at 2mg/kg, reduce to 1mg/kg daily rather than skipping days. Animal models show that even suboptimal daily dosing (0.5mg/kg) produces measurable ROS reduction, while high-dose intermittent protocols produce inconsistent results.

Verify three variables before concluding non-response: peptide purity (demand certificate of analysis with HPLC and MS data), reconstitution technique (injection of air into the vial contaminates every subsequent draw), and tissue-specific cardiolipin content. Some tissues. Liver, lung. Have lower baseline cardiolipin than cardiac or renal tissue and may require doses above 3mg/kg to saturate binding sites. The alternative explanation is that cardiolipin disruption isn't the primary mitochondrial dysfunction mechanism in your model. SS-31 won't rescue dysfunction driven by mtDNA depletion, electron transport chain subunit deficiency, or substrate availability issues.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed, then resume the regular schedule. If more than 12 hours late, skip that dose entirely and continue the next day. Do not double-dose. SS-31 has a plasma half-life of approximately 1.5 hours, meaning one missed dose creates a 24-hour gap in mitochondrial protection, but doubling the next dose increases hypotension risk without recovering that gap.